First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible

Abstract

Imaging of neuroendocrine tumors with sst antagonists is clinically feasible. The favorable human biodistribution data suggest that sst antagonists could significantly affect peptide receptor-mediated imaging and therapy.